Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification

By afschroeder • July 2, 2025

Strober B, Patel M, Kaldas MI, St John G, Photowala H, Sima AP, Eckmann T, Beeghly A, Armstrong A. Real-World Skin Clearance and Quality of Life with risankizumab in Patients with Psoriasis with Moderate Skin Involvement and Those Eligible for Systemic Therapy Per International Psoriasis Council Classification. Dermatol Ther (Heidelb). 2025 Jul 2. doi: 10.1007/s13555-025-01474-3. Epub ahead of print. PMID: 40593269.

Tags: CorEvitas Psoriasis Registry, Dermatology, International Psoriasis Council disease reclassification, National Psoriasis Foundation treat-to-target goals, patient-reported outcomes, psoriasis, Publications, real-world, risankizumab, Skin clearance, Systemic-eligible

Related Posts

The Epidemiology of Atopic Dermatitis Among Adults and Adolescents with Alopecia Areata in the United States

Bunick CG, Armstrong AW, Grada A, Soliman AM, Li C, Bristow CC, Khan IA, Lipiszko D, Silverberg JI, Issa NT, Mostaghimi A. The Epidemiology of[...]

Dynamics of Th1/Th17 responses and antimicrobial pathways in leprosy skin lesions

Andrade PR, Ma F, Lu J, de Anda J, Lee EY, Agak GW, Dobry CJ, de Andrade Silva BJ, Teles RM, Mansky LA, Perrie J,[...]

Mammary tissue microbiome analysis in PyMT mice reveals Methylobacteria as a commensal organism with potential therapeutic applications

Chan AA, Caron C, Navarrete M, Lee CK, Noguti J, Bui JD, Lee DJ. Mammary tissue microbiome analysis in PyMT mice reveals Methylobacteria as a[...]